Tevogen Bio Holdings (TVGN) Net Income towards Common Stockholders (2022 - 2026)
Tevogen Bio Holdings (TVGN) reported Net Income towards Common Stockholders of -$5.6 million for Q1 2026, up 46.48% on a YoY basis from -$3.8 million in Q1 2025, and down 16.68% quarter-over-quarter from -$4.8 million in Q4 2025.
Tevogen Bio Holdings (TVGN) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$5.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 46.48% year-over-year to -$5.6 million; the trailing twelve-month figure through Mar 2026 stood at -$21.9 million (up 31.21% YoY), and the FY2025 full-year result was -$26.8 million, down 161.11% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.6 million, down from -$4.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $10.5 million in Q1 2024, with the low at -$10.5 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$2.8 million across 5 years, with a median of -$3.9 million in 2023.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders surged 3720.76% — and 2024, when it plunged 4010.96%.
- Tevogen Bio Holdings' Net Income towards Common Stockholders stood at $1.8 million in 2022, then tumbled by 298.75% to -$3.6 million in 2023, then plunged by 159.05% to -$9.4 million in 2024, then jumped by 48.8% to -$4.8 million in 2025, then fell by 16.68% to -$5.6 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.6 million (Q1 2026), -$4.8 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Tevogen Bio Holdings | 182.04 Mn | 181.35 Mn | - | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.62 Mn |
| Dec 31, 2025 | -4.82 Mn |
| Sep 30, 2025 | -5.86 Mn |
| Jun 30, 2025 | -5.64 Mn |
| Mar 31, 2025 | -10.50 Mn |
| Dec 31, 2024 | -9.41 Mn |
| Sep 30, 2024 | -5.91 Mn |
| Jun 30, 2024 | -6.08 Mn |
| Mar 31, 2024 | 10.51 Mn |
| Dec 31, 2023 | -3.63 Mn |
| Sep 30, 2023 | -3.90 Mn |
| Jun 30, 2023 | -147,785.00 |
| Mar 31, 2023 | 705,722.00 |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 403,216.00 |
| Jun 30, 2022 | 155,249.00 |
| Mar 31, 2022 | -19,491.00 |